Vogenx, Inc. Listed Primary

What the company does

Vogenx, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. Founded in 2021, the company's primary objective is to advance its lead investigational product candidate, mizagliflozin—an orally administered, minimally absorbed small molecule that selectively inhibits the sodium-glucose transporter 1 (SGLT1)—through clinical development. Mizagliflozin was discovered by Kissei Pharmaceutical Co., Ltd., from which Vogenx obtained exclusive worldwide rights (excluding Japan, Korea, and Taiwan) in 2021.

Use of proceeds

The company estimates net proceeds of approximately $73.6 million from the offering (or $84.9 million if the underwriters exercise their option in full), based on the initial public offering price of $13.00 per share and after deducting underwriting discounts and commissions and estimated offering expenses. It intends to use these net proceeds, together with existing cash and cash equivalents, to fund the continued development of mizagliflozin, payment of accrued expenses, additional research and development, and for general corporate purposes and working capital.

Underwriters

Extracted from 424B4 0001185185-26-003448, filed Aug 12, 2026 and verified against that filing text.

Key risk factors

• Public company compliance costs

  “We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.”